Back to Search
Start Over
Glomerular Diseases
- Source :
- Clinical Journal of the American Society of Nephrology. 9:617-625
- Publication Year :
- 2014
- Publisher :
- Ovid Technologies (Wolters Kluwer Health), 2014.
-
Abstract
- The last decade has seen major progress in understanding the pathogenesis as well as the prognosis and treatment of patients with IgA nephropathy (IgAN). Although the diagnostic criterion of a kidney biopsy demonstrating dominant or codominant IgA deposition remains unchanged, much more is known about the genetic and environmental factors predisposing to disease development and progression. These advances have led to the identification of novel diagnostic and prognostic markers. Among the most promising clinically are genetic profiling, quantification of galactose-deficient IgA1 levels, and measurement of anti-IgA1 immunoglobulins. While targeted treatment for IgAN remains elusive, there is mounting evidence for therapeutic interventions that alter the disease course. The appropriate validation and integration of these discoveries into clinical care represent a major challenge, but one that holds tremendous promise for refining prognostication, guiding therapy, and improving the lives of patients with IgAN.
- Subjects :
- Genetic Markers
Immunoglobulin A
Epidemiology
Biopsy
Kidney Glomerulus
Disease
Critical Care and Intensive Care Medicine
Bioinformatics
Nephropathy
Pathogenesis
Humans
Medicine
Glomerular diseases
Autoantibodies
Tonsillectomy
Transplantation
medicine.diagnostic_test
biology
business.industry
Autoantibody
Glomerulonephritis, IGA
Glomerulonephritis
medicine.disease
Treatment Outcome
Nephrology
Immunology
biology.protein
business
Immunosuppressive Agents
Moving Points in Nephrology
Subjects
Details
- ISSN :
- 15559041
- Volume :
- 9
- Database :
- OpenAIRE
- Journal :
- Clinical Journal of the American Society of Nephrology
- Accession number :
- edsair.doi.dedup.....20c57728315308f6daa8b909e7724054